Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes

Abstract

The aim of this study was to evaluate the impact of adipocyte fatty acid binding protein 4 (FABP4) on the lipid profile in type 2 diabetic subjects. Plasma levels of FABP4 and adiponectin and an extensive lipid profile were analyzed in 169 type 2 diabetic subjects and 105 controls. Type 2 diabetic subjects were categorized according the presence of atherogenic dyslipidemia. Univariate statistical analyses, partial correlation tests, and binary logistic regression models were applied. In type 2 diabetic subjects, FABP4 was positively correlated with plasma triglycerides (P 5 0.007), apolipoprotein C-III (apoC-III) (P 5 0.009), and all the components of triglyceride-rich lipoproteins, including VLDL triglycerides (P 5 0.002), VLDL-cholesterol (P 5 0.001), and VLDL apoB (P 5 0.001). FABP4 was inversely correlated with apoA-I (P 5 0.038), HDL-cholesterol (P 5 0.002), and HDL apoA-I (P 5 0.010) in type 2 diabetic subjects. These correlations are not significantly affected by age, gender, body mass index, adiponectin, insulin, or any pharmacological treatment. The associations are even stronger when the FABP4/adiponectin ratio is considered. None of these associations were observed in controls. High FABP4 and low adiponectin levels are independent predictors of atherogenic dyslipidemia. In conclusion, FABP4 plasma concentrations hold strong potential for development as a clinical biomarker for atherogenic dyslipidemia, independent of obesity and insulin resistance, in type 2 diabetic subjects.-Cabré, A., I. Lázaro, J. Girona, J. M. Manzanares, F. Marimón, N. Plana, M. Heras, and L. Masana. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J. Lipid Res.

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

“…In agreement with these findings, serum AFABP values were positively and independently correlated with markers of the metabolic syndrome, including waist circumference, blood pressure, dyslipidaemia, fasting insulin and HOMA of insulin resistance, in the initial study [59]. A similar association of circulating AFABP with facets of the metabolic syndrome has also been shown in other studies [12,66,67,[70][71][72][73].…”

Fasting Serum Level of Fatty-Acid-Binding Protein 4 Positively Correlates With Metabolic Syndrome in Patients With Coronary Artery Disease

“…25 In patients with diabetes, FABP4 positively correlates with plasma levels of TG, apolipoprotein C-III, and all the components of TG-rich lipoproteins, including very low-density lipoprotein (VLDL) TG, VLDL-C, and VLDL apoB. 26 Cabré et al also noted that plasma levels of FABP4 are increased in familial combined hyperlipidemia, 27 which manifests as increased production of TG-rich lipoproteins, mainly liver-derived VLDL, with the ensuing hyperlipidemia characterized by increased plasma levels of both TG and cholesterol. 28 Our study of CAD patients also noted that serum levels of TG and LDL-C positively correlated with the fasting serum level of FABP4, and that HDL-C had a negative correlation.…”

Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus

“…Furthermore, elevated serum concentration of FABP4 has been shown to be associated with obesity, insulin resistance, type 2 diabetes mellitus, hypertension, cardiac dysfunction, renal dysfunction, dyslipidemia, atherosclerosis, and cardiovascular events ( 8,(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). However, little is known about the modulation of serum FABP4 level by therapeutic drugs including antidiabetic agents except for thiazolidinedione ( 25 ).…”